Skip to main content

Table 3 Subgroup Analyses of the Associations between LMR and progression free survival

From: Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis

Variables

No. of studies

Test of association

Test of heterogeneity

HR

95% CI

P value

I2 (%)

P value

Total

9

0.598

0.465–0.768

< 0.001

89.00

< 0.001

Publication year

 ≤ 2016

4

0.526

0.355–0.777

0.001

83.10

< 0.001

 > 2016

5

0.66

0.470–0.881

0.006

89.60

< 0.001

Initial inclusion period

 ≤ 2006

3

0.502

0.299–0.843

0.009

88.70

< 0.001

 > 2006

6

0.648

0.47–0.882

0.006

89.60

< 0.001

Nationality

      

 China

8

0.561

0.466–0.675

< 0.001

64.40

0.006

 Japan

1

1

0.896–1.116

1

–

–

Number of cases

 < 200

4

0.684

0.450–1.040

0.075

83.10

< 0.001

 > 200

5

0.551

0.429–0.707

< 0.001

77.60

0.001

Median age (years)

 ≤ 60

5

0.546

0.408–0.729

< 0.001

77.00

0.002

 > 60

4

0.67

0.462–0.971

0.035

87.70

< 0.001

Tumor types

 Cervical carcinoma

1

0.239

0.151–0.379

< 0.001

–

–

 Colon cancer and rectal cancer

2

0.695

0.562–0.861

0.001

0.00

0.713

 Ovarian cancer

1

0.581

0.508–0.664

< 0.001

–

–

 Esophageal cancer

1

0.461

0.31–0.685

< 0.001

–

–

 Lung cancer

4

0.738

0.54–1.007

0.056

80.00

0.002

LMR cutoff

 ≤ 4.0

4

0.609

0.546–0.680

< 0.001

0.00

0.546

 > 4.0

5

0.56

0.351–0.892

0.015

92.20

< 0.001

Therapeutic strategies

 Chemotherapy

4

0.62

0.558–0.688

< 0.001

0.00

0.489

 Molecular targeted

2

0.793

0.472–1.335

0.384

84.10

0.012

 Combined therapy

3

0.415

0.241–0.716

0.002

78.40

0.01

Follow-up period (month)

      

 ≤ 33

4

0.619

0.510–0.751

< 0.001

14.20

0.321

 > 33

3

0.457

0.270–0.774

0.004

85.40

0.001

 NR

2

0.826

0.55–1.239

0.356

88.50

0.003

Quality score

 < 7

2

0.826

0.550–1.239

0.356

88.50

0.003

 ≥ 7

7

0.542

0.435–0.674

< 0.001

67.80

0.005

Analysis of hazard ratio

 Multivariate

8

0.592

0.452–0.776

< 0.001

90.40

< 0.001

 Univariate

1

0.644

0.406–1.021

0.061

–

–

  1. CI confidence interval, HR hazard ratio, No. number; LMR lymphocyte-to-monocyte ratio
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us